Trial Profile
Cannabinoid Control of Fear Extinction Neural Circuits in Post-traumatic Stress Disorder
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Sep 2022
Price :
$35
*
At a glance
- Drugs Dronabinol (Primary)
- Indications Post-traumatic stress disorders
- Focus Pharmacodynamics; Therapeutic Use
- 26 Sep 2022 Results investigating the effect of THC on negative affect and brain activation in a priori regions of interest during cognitive reappraisal among trauma-exposed individuals with and without PTSD, published in the Neuropharmacology
- 16 Aug 2022 According to ClinicalTrials.gov record, protocol has been amended as change in time frame for primary end points from 4yeras to 13-15days.
- 18 May 2020 Status changed from active, no longer recruiting to completed.